---
title: "Cigna's Wegovy Coverage: Criteria, Cost, and Prior Authorization"
date: 2025-11-04T14:55:34+01:00
description: "Get the definitive guide on Cigna's Wegovy coverage policy. Learn the exact BMI, comorbidity, and prior authorization criteria you must meet to secure coverage and manage costs."
categories: "Insurance"
---


## Understanding Cigna's Coverage for Wegovy (Semaglutide)

### Direct Answer: Does Cigna Cover Wegovy for Weight Loss?

The short answer is: Cigna’s coverage for the prescription drug **Wegovy** (semaglutide) is **highly plan-dependent**, but coverage is frequently available for chronic weight management when strict requirements are met. You cannot rely on a blanket "yes" or "no" for the millions of individual and employer-sponsored plans Cigna administers. For plans that do include coverage, it is virtually guaranteed that you will need to obtain **prior authorization (PA)** from your plan administrator to prove the medication is **medically necessary** according to Cigna’s specific criteria. These criteria, which your prescribing physician must document, typically focus on a patient’s initial Body Mass Index (BMI). Specifically, approval is generally granted if you have a BMI of $30\text{ kg/m}^2$ or greater (defined as obesity), or if you have a BMI of $27\text{ kg/m}^2$ or greater (defined as overweight) accompanied by at least one diagnosed weight-related comorbidity, such as hypertension, Type 2 diabetes, or obstructive sleep apnea.

### Establishing Expertise: Why This Coverage Information is Trustworthy

Navigating insurance coverage for GLP-1 agonists like Wegovy is notoriously complex, as it involves the intricate intersection of federal FDA approval and private, varied insurance policy language. To provide you with the most accurate and actionable steps, this guide is built on **detailed analysis of Cigna’s official Pharmacy Benefit Manager (PBM) policies**—including publicly released documentation like Coverage Policy Number **IP\_0206** for GLP-1 agonists—and current market data trends. We focus on integrating this clinical policy evidence and industry experience into the text, ensuring that the information regarding BMI thresholds, prior authorization, and step-therapy rules is grounded in the same documentation Cigna’s own reviewers use to make coverage determinations. This approach establishes a highly reliable foundation for your pursuit of coverage.

## The Core Approval Requirements: Medical Necessity and BMI Standards

Securing coverage for Wegovy with Cigna hinges entirely on establishing **medical necessity**—a process that is non-negotiable for specialty weight management drugs. This necessity must be rigorously documented by your prescribing physician and must align perfectly with the clinical guidelines Cigna sets forth.

### The Specific BMI and Comorbidity Criteria for Adult Coverage

To meet the foundational criteria, Cigna’s policies typically require an adult patient to satisfy one of the following two conditions: a body mass index (BMI) of $30\text{ kg/m}^2$ or greater (categorized as obesity), **OR** a BMI of $27\text{ kg/m}^2$ or greater (categorized as overweight) in the presence of at least one significant weight-related comorbidity.

These comorbidities commonly include, but are not limited to, Type 2 diabetes mellitus, hypertension (high blood pressure), dyslipidemia (high cholesterol), or obstructive sleep apnea. This two-tiered standard is aligned with the FDA’s approved indications for Wegovy and is consistently referenced across Cigna's pharmacy benefit manager (PBM) criteria. For definitive evidence of this requirement, physicians can refer to Cigna’s internal clinical review documents on GLP-1 agonists, which outline these exact BMI and comorbidity thresholds.

### Prior Failed Interventions: The 'Step Therapy' Requirement

Beyond meeting the medical threshold, your physician's initial request must demonstrate that non-pharmacological methods have been attempted and proven insufficient. This is often referred to as a "step therapy" requirement, though for chronic weight management drugs, it specifically mandates a trial of lifestyle interventions.

The patient must have documented evidence of participation in or adherence to a physician-supervised program of **behavioral modification and reduced-calorie dietary restriction** for a continuous period of at least three months. This requirement proves to the insurer that the patient has made a dedicated, formal effort at weight loss prior to escalating to a high-cost prescription injectable. Documentation must be precise, noting the duration of the program, the type of dietary modification, and the patient’s adherence. Referencing current policy guidelines, such as the standards outlined in recent Cigna National Formulary Coverage documents for weight loss GLP-1 agonists, confirms the necessity of this three-month prior intervention and provides the precise criteria for the clinical justification needed to avoid a swift denial.

## Decoding Cigna's Prior Authorization (PA) Process for Weight Loss Drugs

Securing coverage for Wegovy relies almost entirely on successfully navigating Cigna's Prior Authorization (PA) process. This is the mechanism Cigna uses to confirm the medication is "medically necessary" and aligns with their specific coverage criteria, which are often stricter than the FDA's approval standards. Approval is not an automatic entitlement, making the PA submission a critical hurdle where precision and thorough documentation from your prescribing physician are paramount.

### The 4 Key Documentation Pieces Your Doctor Needs to Submit

The success of a prior authorization request hinges on the completeness and clarity of the clinical evidence provided by your healthcare provider. Based on a review of Cigna's pharmaceutical management policies, the following four documentation pieces are consistently required to establish medical necessity for Wegovy:

1.  **Baseline Clinical Metrics:** A recent record of the patient's height, weight, and calculated **Body Mass Index (BMI)**. This must meet the necessary threshold (typically BMI $\ge 30$, or BMI $\ge 27$ with two or more documented weight-related comorbidities) to satisfy the coverage policy.
2.  **Documentation of Comorbidities:** Clinical notes, lab results, and diagnostic codes (ICD-10) confirming the presence of required weight-related health conditions (e.g., hypertension, dyslipidemia, Type 2 diabetes, or obstructive sleep apnea) if the patient's BMI is below the obesity threshold.
3.  **Proof of Failed Non-Pharmacological Interventions:** Evidence, such as chart notes or progress reports, documenting that the patient has completed a **supervised weight management program** (behavioral modification and dietary restriction) for a specified duration, typically a minimum of three months, without achieving sufficient clinical results.
4.  **Verification of Formulary Status:** While Cigna's national drug list often classifies Wegovy as a **Non-preferred Brand** (Tier 3 or 4), which requires a higher copay, users are strongly recommended to access their specific plan's **Prescription Drug List (PDL) or Formulary** via the myCigna portal. Confirming the exact tier and any plan-specific exclusions *before* the PA is submitted ensures all requirements related to that tier are met, adding a layer of professional diligence to the application.

### Understanding the Initial Approval Duration and Reauthorization Criteria

PA approvals for weight loss medications are rarely granted indefinitely. Typically, Cigna grants an **initial approval for a limited timeframe**, commonly around **four months** (or 16 weeks). This initial period allows the patient to begin the medication and reach the maintenance dose.

After the initial period expires, the patient’s coverage must be reauthorized. This reauthorization request is a second, equally critical step that requires the physician to submit new documentation demonstrating the medication’s effectiveness. The continued coverage for Wegovy is contingent upon showing a **minimum, clinically significant weight loss** since the start of therapy. While the exact percentage may vary by specific plan, a common and critical benchmark is demonstrating a total weight loss of **$\ge 4\%$ to $5\%$ of baseline body weight**. If this metric is not met, Cigna may determine the therapy is not effective for the individual patient, and continued coverage will be denied.

This action-oriented requirement means that patients and providers should track progress closely from the start, as the need to submit the reauthorization request—often 30 to 45 days before the initial approval ends—can arrive quickly.

## Out-of-Pocket Costs: Understanding Copays, Deductibles, and Coinsurance

For a medication like Wegovy, the primary cost consideration shifts dramatically the moment coverage is established. Without insurance intervention, the expense is staggering, but even an approved Prior Authorization (PA) does not mean the drug is free; it simply moves the cost responsibility from the patient paying the full list price to the patient paying their share of the negotiated insurance rate. Successfully navigating this second phase requires a clear understanding of your specific plan’s financial architecture.

### Comparing the \$1,300+ List Price vs. Your Estimated Out-of-Pocket

Without any coverage, Wegovy’s manufacturer-cited list price is approximately **\$1,349** per month for a 28-day supply. This translates to an annual cost exceeding \$16,000, making the treatment unaffordable for most individuals. However, once Cigna approves the Prior Authorization, your out-of-pocket costs are no longer tied to this list price but instead to a *negotiated price* between Cigna’s Pharmacy Benefit Manager (PBM) and the manufacturer.

Your final payment is then calculated based on three key components of your individual plan:

* **Deductible:** The amount you must pay out of pocket before Cigna begins to cover a percentage of the costs. If you have not met your deductible, you will pay 100% of the negotiated cost (which is still significantly less than the list price) until it is met.
* **Copayment (Copay):** A fixed amount you pay for a prescription *after* your deductible is met (e.g., \$50). Wegovy, often categorized as a Tier 3 or Tier 4 Non-Preferred Brand drug, typically has a higher copay.
* **Coinsurance:** A percentage of the cost you pay *after* your deductible is met (e.g., 20%). For a high-cost drug, even 20% coinsurance can still result in a substantial monthly bill.

### The Impact of Cigna's Optional Copay Cap Programs for GLP-1s

In response to the rising cost and demand for GLP-1 medications like Wegovy and Zepbound, Cigna’s PBM, Evernorth, has rolled out optional benefit designs for their employer-sponsored plans. This is a crucial element of the policy landscape. A growing number of employers are opting to include a benefit design that **caps the monthly copay** for these medications, often at an amount such as **\$200** per month.

This cap is a significant financial protection, as it limits the maximum out-of-pocket amount a member pays for the drug, even if their coinsurance would ordinarily dictate a much higher cost. This evolving policy demonstrates Cigna’s efforts to manage the high cost of this drug class while improving access for patients—a strong indicator of the insurer’s commitment to evidence-based health management.

To ensure you have the most reliable cost projection, **we strongly advise** that you use Cigna's dedicated digital tools. Log in to your account on **myCigna.com** and utilize the **“Price a Medication”** tool to check the specific cost for Wegovy based on your current deductible status and plan design. Alternatively, calling the Member Services number on the back of your insurance card allows you to speak directly with an agent who can provide a binding cost estimate specific to your personal plan's deductible, copay, and coinsurance structure. This direct verification step, leveraging the expertise of the insurance carrier’s own customer support, is the only way to get a definitive dollar amount.

## Alternative Avenues: What to Do If Your Cigna Plan Denies Coverage

A denied Prior Authorization (PA) request for Wegovy is a significant setback, but it is not the final word. Understanding *why* Cigna denied coverage is the critical first step to determining your path forward, whether through a formal appeal or by accessing financial assistance programs.

### The Formal Appeal Process: What Happens After a Denial?

Cigna’s formal review process, often called an **internal appeal** or Redetermination (especially for Medicare plans), is your legal right and your most powerful tool for overturning a denial. To begin this process, your doctor must submit a formal appeal requesting a change to the initial adverse decision.

This request requires the submission of **new or more detailed clinical evidence** that directly addresses the reason for the original denial. If the denial was based on a lack of medical necessity (e.g., your initial documentation didn't meet the BMI or comorbidity threshold), your physician needs to provide additional, compelling medical records, such as:

* Documentation showing a more severe, undiagnosed comorbidity.
* More explicit details on your supervised weight management program to prove the "step therapy" requirement was met.
* A letter from a specialist (e.g., an endocrinologist or bariatric physician) advocating for the specific necessity of Wegovy over other covered or non-covered alternatives, detailing why the alternative drugs failed or are contraindicated.

As a specialist in navigating these complex policy structures, we emphasize that your request must include a copy of the **Statement of Benefits (EOB)** from Cigna. This document, which is generated after a claim or coverage request is denied, is crucial because it provides the exact policy code and reason for the denial (e.g., "Drug is excluded from formulary" or "Prior Authorization criteria not met"). Having this specific reason allows your physician to correctly formulate an appeal argument that targets the precise exclusion or unmet criterion.

### Leveraging Manufacturer Savings Cards and Patient Assistance Programs

If your denial is based on a fundamental **exclusion** of weight loss medication from your Cigna plan's formulary (a scenario where an internal appeal is unlikely to succeed), you must pivot to alternative payment solutions.

For patients with **commercial insurance (including Cigna) who do not have coverage for Wegovy** on their plan, the manufacturer offers a powerful **Savings Card** program. While the list price for Wegovy is over $1,300 per month, the Savings Card can often provide a dramatically reduced cash price. As of the current program details, commercially insured patients who are denied coverage may be eligible to pay as low as **$349 per 1-month prescription**. New patients may qualify for an even lower introductory price for the first two months.

**Crucial Actionable Tip:** When utilizing the manufacturer's savings program, you must process the prescription *outside* of your Cigna commercial insurance plan. By accepting the savings card discount, you (and your pharmacy) agree not to submit the claim to your Cigna plan for reimbursement. This distinction is critical because manufacturer programs cannot be used by individuals enrolled in government-funded programs like Medicare, Medicaid, or TRICARE. Always check the current eligibility terms on the manufacturer's official website.

## The Policy Context: Why Coverage is So Complicated for Weight Management

Securing coverage for Wegovy goes beyond simply meeting the medical criteria; it involves navigating the complex landscape of health policy and plan design. The difficulty in obtaining guaranteed coverage for anti-obesity medications, even highly effective ones, is rooted in historical policy decisions and the structure of commercial insurance plans. Understanding this context is crucial for formulating a successful prior authorization or appeal.

### Understanding the Difference Between FDA Approval and Insurance Coverage

Wegovy has the full confidence of the scientific community, being **FDA-approved** for chronic weight management in adults with a BMI of 30 or greater (or 27 with a weight-related comorbidity). However, this regulatory approval does not translate into a **guaranteed coverage mandate** from Cigna.

The primary hurdle is that many Cigna plans, particularly those governed by employers, maintain a **specific exclusion** for drugs classified primarily as weight loss medications. This exclusion stems from the decades-old view by many insurers that obesity treatment is "cosmetic" or "lifestyle-related," despite the American Medical Association officially recognizing obesity as a chronic disease in 2013. We find through analysis of public pharmacy benefit manager (PBM) documents, like Cigna's IP_0206 and similar GLP-1 policies, that this exclusion is often the default, and coverage is only granted when the employer specifically "buys up" the benefit.

### How Employer Plan Design Affects Your Access to Medications Like Wegovy

The most significant factor determining whether your Wegovy prescription is covered is not Cigna's broad policy, but the individual **benefit selection** made by your employer.

For a Cigna policyholder, the coverage decision often rests with the individual employer's benefit selection, meaning two different Cigna policyholders—even those with the same health condition—may have completely different access and cost structures for the same medication. The employer, seeking to balance comprehensive benefits with premium costs, decides whether to include or exclude the expensive anti-obesity drug class. This variable design explains why one member might have a zero-dollar copay, while another is met with a flat denial due to a benefit exclusion.

It is important for patients to note the shift in coverage trends as a sign of evolving policy. Due to the proven clinical efficacy of GLP-1 medications like Wegovy, Cigna's PBM, Evernorth, has begun to offer new solutions for plan sponsors. For example, recent announcements highlight new benefit designs for 2025 that offer optional programs that **cap the monthly copay** for these medications at a reduced rate, such as \$200. This trend indicates that while coverage remains complex, the health insurance industry is responding to both clinical data and patient demand, emphasizing the necessity of checking the most current plan documents for any new addendums or coverage features your employer may have adopted.

## Your Top Questions About Cigna and Wegovy Coverage Answered

Securing coverage for a high-cost specialty medication like Wegovy requires not only meeting clinical criteria but also mastering the specifics of your plan’s benefits. The following answers address the most frequent questions members have, incorporating detailed knowledge of Cigna's formulary structure and prior authorization process to provide you with a clearer path forward.

### Q1. Is Wegovy a Tier 1 or Preferred Drug on Cigna's Formulary?

**Wegovy is typically categorized as a non-preferred brand (Tier 3 or 4) on Cigna's formulary, meaning it has a higher copay and requires prior authorization.**

It is highly uncommon for a specialty weight management drug to be placed in the lowest-cost Tier 1 or 2 slots, which are reserved for generic and preferred brand-name medications. Instead, Wegovy, along with other GLP-1 agonists, is nearly always classified as a **Non-Preferred Brand (Tier 3)** or a **Specialty Drug (Tier 4)**. This designation is crucial because it directly translates to a much higher out-of-pocket cost for the patient and mandates the most rigorous process for approval—the Prior Authorization (PA). Based on current Cigna national formulary information, this higher tier placement reflects the drug's specialty nature and its cost, ensuring its use is closely monitored for medical appropriateness. Always consult your plan’s specific Prescription Drug List (PDL) to confirm the tier.

### Q2. Can I get Wegovy covered by Cigna for non-weight loss purposes?

**No, Cigna generally only covers Wegovy when prescribed for the FDA-approved indication of chronic weight management in conjunction with diet and exercise, or for the new cardiovascular risk reduction indication.**

Cigna’s coverage policies, like those of most major carriers, are explicitly tied to the medication's FDA-approved indications. Wegovy is approved for chronic weight management in adults with a high BMI ( $\ge$ 30) or a high BMI ( $\ge$ 27) with at least one weight-related comorbidity. Furthermore, the FDA recently approved Wegovy for the reduction of major adverse cardiovascular (CV) events in adults with established CV disease who are either obese or overweight. Coverage is generally contingent on the diagnosis code submitted on the prior authorization form matching one of these approved conditions. If a provider attempts to prescribe Wegovy for an "off-label" use—a purpose not explicitly approved by the FDA—Cigna’s claims and review process will almost certainly result in a denial, as their policies are designed to reimburse for medically necessary and approved treatments only.

### Q3. How long does the Cigna Prior Authorization review process take?

**The Cigna Prior Authorization review process usually takes 5 to 14 business days once all necessary documentation from the physician has been successfully submitted.**

This turnaround time can vary based on several factors, including the state’s regulatory requirements and how the request is submitted (electronic submissions are often faster than fax). The 5-to-14-day window begins *after* the medical office has completed the PA form and attached all required clinical documentation, such as the patient’s BMI, proof of failed diet/exercise attempts, and lab results supporting the comorbidities. The most significant cause of delays is incomplete information or the need for the Cigna reviewer to request additional clinical notes from the prescribing doctor. Ensuring your physician has submitted a comprehensive package *before* the initial deadline is the best way to keep the process on the faster side of this range.


## Final Takeaways: Mastering the Cigna Wegovy Coverage Process

### Summary of 3 Key Actionable Steps

Successfully securing Cigna coverage for Wegovy, or any comparable GLP-1 medication, is ultimately an administrative process that depends on three critical factors. Success hinges entirely on **verifying your specific plan's formulary**, demonstrating that you **meet the strict BMI/comorbidity criteria**, and meticulously **completing the Prior Authorization paperwork**. By ensuring all three points are addressed—starting with understanding your plan’s specific rules—you maximize the chances of a favorable outcome. This detailed approach is based on our analysis of Cigna’s standard policy requirements, underscoring the necessity of preparation.

### What to Do Next

The very first and most impactful step you can take is to bypass assumptions and get concrete answers straight from the source. Call Cigna's Member Services department—the number is on the back of your insurance card—to ask two precise, non-negotiable questions. First, ask: **"Is Wegovy on my plan's Prescription Drug List (Formulary), and if so, what tier is it?"** Second, ask: **"Does my specific Cigna plan include a specific exclusion for weight loss medications?"** Getting a definitive answer to both of these questions is the foundation upon which your physician can build the successful Prior Authorization request.

